[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-337353-105":59,"doc-detail-337353-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","tert-promoter-mutations-frequency-across-race-sex-and-cancer-type","TERT Promoter Mutations Frequency Across Race, Sex, and Cancer Type","","Background: Telomerase reverse transcriptase (TERT) gene promoter mutations have been investigated as biomarkers of improved survival for cancer patients receiving immune checkpoint inhibitors. This study assessed their prevalence across race and sex among multiple cancer types to support patient selection in clinical trials. Results: In an observational cohort of 31,925 patients, TERT promoter mutations differed by race and cancer type, and also varied by sex within several cancers. Conclusions: TERT promoter mutation prevalence is stratified by race and sex, informing cancer biology and trial design targeting TERT dependencies.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/tert-promoter-mutations-frequency-across-race-sex-and-cancer-type/337353/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/tert-promoter-mutations-frequency-across-race-sex-and-cancer-type/337353.png","ImageObject",300,407,{"name":92,"@type":93},"Jiven","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-22","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the study’s main goal regarding TERT promoter mutations?","Question",{"text":112,"@type":113},"To evaluate the prevalence of TERT promoter mutations by race and sex across different cancer types, supporting patient selection in clinical trials.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were TERT promoter mutations analyzed in the study?",{"text":117,"@type":113},"The study used next-generation sequencing of tumor samples from 31,925 patients with cancer and examined distributions by race and sex across cancer types.",{"name":119,"@type":110,"acceptedAnswer":120},"Did the prevalence of TERT promoter mutations differ by race and by sex?",{"text":121,"@type":113},"Yes. The distribution varied by race across cancer types (e.g., melanoma, head and neck cancer) and also differed by sex within multiple cancers.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},337353,1790118925,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":34,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},1099513958607,"https://ap-avatar.wpscdn.com/avatar/100002390cf8733938c?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778829742770036399","TERT Promoter Mutations Frequency Across Race, Sex, and Cancer Type  \nTalal El Zarif1,2,3,‡,, Marc Machaalani4,‡, Rashad Nawfal4,‡, Amin H. Nassar5, Wanling Xie6,, Toni K. Choueiri1,2,, Mark Pomerantz1,2,*,  \n1Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA, USA 2Department of Medicine, Harvard Medical School, Boston, MA, USA  \n3Department of Internal Medicine, Yale New Haven Hospital, New Haven, CT, USA 4Faculty of Medical Sciences, Lebanese University, Beirut, Lebanon  \n5Department of Hematology/Oncology, Yale New Haven Hospital, New Haven, CT, USA 6Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA  \n* Corresponding author: Mark Pomerantz, MD, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute and Harvard Medical School, 450  \nBrookline Avenue, Boston, MA 02215, USA. Tel: +1 617 632 4524; [Email:](Email: mark_pomerantz@dfci.harvard.edu)[ mark_pomerantz@dfci.harvard.edu](Email: mark_pomerantz@dfci.harvard.edu)[ ](Email: mark_pomerantz@dfci.harvard.edu)‡Contributed equally.  \nAbstract  \nBackground: Telomerase reverse transcriptase ( TERT) gene promoter mutations have been explored, as biomarkers of improved survival for patients with cancer receiving immune checkpoint inhibitors. We sought to investigate their prevalence by race and sex across different cancer types to inform patient selection in clinical trials.  \nResults: In this observational study, 31 925 patients with cancer underwent next-generation sequencing of their tumors with 88%(27 970) patients self-reported being Whites, 7. 1%(2273) Asians, and 5.3%(1682) Blacks. Examining the distribution of TERT promoter mutations by race, White patients with melanoma harbored more TERT promoter mutations than Asian and Black patients (OR = 25.83; 95%CI, 6.84-217.42; P \u003C .001) . In contrast, Asian patients with head and neck cancer (HNC) harbored more TERT promoter mutations compared to White patients (OR = 2.47; 95%CI, 1.39-4.37; P = .004) . In addition, the distribution of TERT promoter mutations differed by sex . Males were enriched for TERT gene promoter mutations compared to females with melanoma (OR = 1.82; 95%CI, 1.53-2. 16; P \u003C .001), cancer of unknown primary (OR = 1.96; 95%CI, 1.43-2.69; P \u003C .001), hepatobiliary (OR = 3.89; 95%CI, 2.65-5.69; P \u003C .001), and thyroid cancers (OR = 1.42; 95%CI, 1.10- 1.84; P = .0087), while females were more enriched for TERT promoter mutations compared to males for HNC (OR = 0. 56; 95%CI, 0.39-0.81; P = .0021) .  \nConclusions: The prevalence of TERT gene promoter mutations varies among patients with cancer based on race and sex. These findings inform our understanding of cancer biology and can assist in the design of future clinical trials that leverage drugs targeting TERT promoter dependencies.  \nKey words: TERT mutation; disparities in cancer care; immune checkpoint inhibitor.  \nImplications for Practice  \nThe findings of this study illustrate that there are major differences in the prevalence of TERT promoter mutations in various cancer types across patient populations when stratifying them by sex and ethnic groups. The data presented in this work highlight the necessity of investing more resources in mutation analyses of non-White populations. These efforts will mitigate racial disparities, assist in equitable future clinical trial design, and potentially lead to better biological insights that can justify the observed differences in mutational landscapes.  \nIntroduction  \nTelomerase is a reverse transcriptase that synthesizes the 3ʹ end of linear chromosomes.1,2 In human somatic cells, telomeres shorten with each cellular replication, as DNA polymerase cannot fully replicate the 3ʹ end of DNA.3,4 Telomere shortening is a cardinal feature of the aging process, where cells undergo senescence, apoptosis, or genomic instability.5 Telomerase counteracts this process by adding telomeres and is inhibited in most normal human cells across different tissue  \ntypes. ","cbCaiodARV2ivh1s","https://ap.wps.com/l/cbCaiodARV2ivh1s","pdf",2128693,"English","# Abstract\n## Background\n## Results\n## Conclusions\n# Implications for Practice\n# Introduction","[{\"question\":\"What was the study’s main goal regarding TERT promoter mutations?\",\"answer\":\"To evaluate the prevalence of TERT promoter mutations by race and sex across different cancer types, supporting patient selection in clinical trials.\"},{\"question\":\"How were TERT promoter mutations analyzed in the study?\",\"answer\":\"The study used next-generation sequencing of tumor samples from 31,925 patients with cancer and examined distributions by race and sex across cancer types.\"},{\"question\":\"Did the prevalence of TERT promoter mutations differ by race and by sex?\",\"answer\":\"Yes. The distribution varied by race across cancer types (e.g., melanoma, head and neck cancer) and also differed by sex within multiple cancers.\"}]","TERT Promoter Mutations Frequency Across Race, Sex, and Cancer Type | PDF",1790018743,18,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b43e8ac1fd865cb8d6aa7727682dc867.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/780abd02ae52e04f022f781e221d1f0a.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f36d00f0f40759fb6375ea98f3bed9a8.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/61f188a928fef6609a17c50c740dbe9f.webp",980,1287]